Published in J Neurosci Res on February 01, 1998
The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling. Dev Biol (2006) 1.85
Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev (1999) 1.37
Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med (1998) 1.24
Neurofibromatosis type 2. J Med Genet (2000) 1.22
Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci (2010) 1.21
Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol (2000) 1.16
The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J (2001) 1.15
The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol (2002) 1.04
Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett (2014) 1.03
A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation. PLoS One (2010) 1.02
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
A systematic screen for dominant second-site modifiers of Merlin/NF2 phenotypes reveals an interaction with blistered/DSRF and scribbler. Genetics (2001) 0.95
Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet (2000) 0.94
Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics (2007) 0.93
Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene. BMC Evol Biol (2005) 0.92
Essential function of protein 4.1G in targeting of membrane protein palmitoylated 6 into Schmidt-Lanterman incisures in myelinated nerves. Mol Cell Biol (2011) 0.90
Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res (2009) 0.89
Fluorescence resonance energy transfer analysis of merlin conformational changes. Mol Cell Biol (2010) 0.89
The role of Drosophila Merlin in spermatogenesis. BMC Cell Biol (2008) 0.87
The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J (2002) 0.87
Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci (2011) 0.87
Role of Merlin/NF2 inactivation in tumor biology. Oncogene (2015) 0.85
Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr (2007) 0.83
A neuronal function of the tumor suppressor protein merlin. Acta Neuropathol Commun (2014) 0.83
Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity. J Cell Mol Med (2012) 0.80
Structure of dimerized radixin FERM domain suggests a novel masking motif in C-terminal residues 295-304. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.78
Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. PLoS One (2014) 0.77
Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains. Biochem J (2001) 0.76
Loss of Merlin induces metabolomic adaptation that engages dependence on Hedgehog signaling. Sci Rep (2017) 0.75
Merlin Isoforms 1 and 2 Both Act as Tumour Suppressors and Are Required for Optimal Sperm Maturation. PLoS One (2015) 0.75
[Hereditary tumor syndromes in neuropathology]. Pathologe (2017) 0.75
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics (1991) 2.03
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet (2000) 1.76
Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology (2001) 1.54
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43
A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol (1993) 1.43
Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29
Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet (2000) 1.27
Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol (2007) 1.22
Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol (2001) 1.21
Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology (2004) 1.17
NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol (2001) 1.16
Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol (2000) 1.16
Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2007) 1.14
Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol (2000) 1.14
Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology (2006) 1.09
Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet (2000) 1.09
The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol (2001) 1.08
Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene (2011) 1.05
Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis (1995) 1.02
Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia (2001) 0.99
Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet (1993) 0.99
Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med (2001) 0.97
The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol (2009) 0.97
Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience (2010) 0.96
miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene (2012) 0.95
The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology (2006) 0.95
Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res (1997) 0.94
Ezrin, radixin, and moesin are components of Schwann cell microvilli. J Neurosci Res (2001) 0.94
Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J Neurosci Res (1996) 0.94
Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene (2006) 0.93
Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci Lett (1996) 0.93
The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. Cell Growth Differ (1995) 0.92
Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol (2009) 0.92
Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1. Eye (Lond) (2011) 0.89
The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet (2000) 0.88
Molecular analysis of malignant triton tumors. Hum Pathol (1999) 0.87
Merlin: hanging tumor suppression on the Rac. Trends Cell Biol (2001) 0.87
Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene (2010) 0.87
Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP. Oncogene (1994) 0.87
Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int J Oncol (1999) 0.86
Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci (1998) 0.85
The ecology of brain tumors: lessons learned from neurofibromatosis-1. Oncogene (2010) 0.85
Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor. Neurology (2006) 0.83
Overexpression of bax in human glioma cell lines. J Neurosurg (1999) 0.83
Characterization and expression of H-21 region gene products on bone marrow-derived macrophages. Eur J Immunol (1982) 0.83
Expression of the neurofibromatosis 1 (NF1) gene during growth arrest. Neuroreport (1996) 0.82
Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues. Neurobiol Dis (1996) 0.81
Genome-wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma. Neuropathol Appl Neurobiol (2011) 0.81
Oculodentodigital dysplasia with cerebral white matter abnormalities in a two-generation family. Am J Med Genet (1995) 0.81
Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol (1997) 0.81
Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia. J Neurosci Res (1996) 0.80
Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet (2000) 0.80
Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. Neuroreport (1995) 0.80
Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol (1996) 0.80
Integrated MR imaging and proton nuclear magnetic resonance spectroscopy in a family with an X-linked spastic paraparesis. AJNR Am J Neuroradiol (1991) 0.80
An alternative apnea test for the evaluation of brain death. Ann Neurol (1991) 0.79
Major histocompatibility complex regulation of the immune response. J Surg Res (1985) 0.79
The question of familial meningiomas and schwannomas: NF2B or not to be? Neurology (2000) 0.79
Neurofibromatosis 2 and malignant mesothelioma. Neurology (2002) 0.79
Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. Arch Dermatol (1996) 0.79
Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration. Dev Dyn (2004) 0.79
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. Neurosurg Focus (1997) 0.78
Ammonium acetate protocol for the preparation of plasmid DNA suitable for mammalian cell transfections. Biotechniques (1997) 0.78
Chromosome 11q23.3-qter deletion and Alexander disease. Am J Med Genet (1991) 0.78
Learning disabilities in neurofibromatosis 1: sizing up the brain. Arch Neurol (1999) 0.78
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg (1998) 0.77
Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell. Am J Pathol (1994) 0.76
Tumor suppressor gene regulation of cell growth: recent insights into neurofibromatosis 1 and 2 gene function. Cell Biochem Biophys (2001) 0.76
Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Fam Cancer (2012) 0.76
In-vitro-derived bone marrow macrophages. Expression of Ia antigens during macrophage differentiation. Transplantation (1984) 0.76
Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1. Neuropathol Appl Neurobiol (2012) 0.76
Comments on neurofibromatosis 1 and optic pathway tumors. Am J Med Genet (2001) 0.75
Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol (1999) 0.75
Limitations of magnetic resonance spectroscopy in patients with white matter disease. Ann Neurol (1994) 0.75
Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report. J Neurosurg (1996) 0.75
Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis. J Neurooncol (1990) 0.75
Characterization of bone marrow derived macrophage as Ia-bearing accessory cells. Adv Exp Med Biol (1982) 0.75
Restriction endonucleases. Am J Med Technol (1983) 0.75
Pseudocervical cord syndrome: a deceptive flumazenil reversible manifestation of hepatic encephalopathy. Arch Neurol (1996) 0.75
Establishing priorities in neurofibromatosis research: a workshop summary. Genet Med (2001) 0.75
Characterization of three new intra-I region recombinant mouse strains, B10.ASR7 (H-2as3), B10.BAR4 (H-2h6), and B10.BASR1 (H-2as4). Immunogenetics (1984) 0.75
The use of restriction endonucleases in the prenatal diagnosis of hemoglobinopathies. Am J Med Technol (1982) 0.75
Separation of the immune response genes for LDH-B and MOPC-173. III. Evidence that the failure of B10.BASR1 to respond to LDH-B is due to an antigen-presenting cell defect. Transplantation (1985) 0.75
Separation of the immune response genes for LDH-B and MOPC-173. I. Description of an immune response defect in B10.BASR1. J Immunol (1983) 0.75
Symptomatic hydrocephalus and reversible spinal cord compression in Listeria monocytogenes meningitis. Case report. J Neurosurg (1989) 0.75
Separation of the immune response genes for LDH-B and MOPC-173. II. Description of an immune response defect in B10.ASR7. J Immunol (1984) 0.75